Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective
Related Experiment Video
Updated: May 13, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Sharef Waadallah Sharef1, Maya Al-Hajri, Ismail Beshlawi
1Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman.
Insights
A lower initial dose of hydroxyurea (HU) in sickle cell disease (SCD) patients is safe and effective. This approach achieved similar clinical benefits to higher doses, reducing vaso-occlusive crises and acute chest syndrome.
Area of Science:
- Hematology
- Pediatric Medicine
- Pharmacology
Background:
- Hydroxyurea (HU) is the standard treatment for severe sickle cell disease (SCD) in children.
- Standard HU dosing ranges from 15-20 mg/kg/day, escalating to 35 mg/kg/day.
- Ethnic neutropenia necessitates careful use of myelosuppressive drugs in certain populations.
Purpose of the Study:
- To evaluate the efficacy and safety of a lower initial dose of HU with cautious dose escalation in pediatric SCD patients.
- To determine if a reduced starting dose impacts treatment outcomes compared to standard protocols.
Main Methods:
- Retrospective and prospective analysis of 161 SCD patients treated with HU at Sultan Qaboos University Hospital (1998-2011).
- Patients received an initial HU dose of 10-12 mg/kg/day, adjusted based on response and side effects.
- Patients were categorized into low-dose (10-15.9 mg/kg/day) and high-dose (16-26 mg/kg/day) groups.
Main Results:
- Significant reductions in annual vaso-occlusive crisis admissions were observed in both low- and high-dose HU groups (P < 0.001).
- No statistically significant difference in efficacy was found between the low- and high-dose groups (P > 0.05).
- Both groups showed comparable improvements in laboratory markers (Hb, MCV, ANC) and clinical outcomes like acute chest syndrome; all patients tolerated treatment well with reversible toxicities.
Conclusions:
- A lower initial dose regimen of HU is a safe and feasible option for managing sickle cell disease in children.
- This approach maintains treatment efficacy without compromising safety, offering a viable alternative for managing SCD.
- Cautious dose escalation ensures optimal therapeutic benefits while mitigating risks associated with myelosuppressive agents.
Background And Objectives:
Hydroxyurea (HU) is the standard treatment for severely affected children with sickle cell disease (SCD). Starting dose is 15-20 mg/kg/day that can be escalated up to 35 mg/kg/day. Ethnic neutropenia is common in this area of the world that requires judicious usage of myelosuppressive drugs. Aim was to assess the efficacy of a lower initial dose of HU and cautious dose escalation regimen in patients with SCD.
Methods:
We assessed 161 patients with SCD on HU, at Sultan Qaboos University Hospital (SQUH), Muscat, Oman, retrospectively from 1998 to 2008 and prospectively from 2009 to 2011. Starting dose of HU was 10-12 mg/kg/day, adjusted based on response or side effects. Patients were divided into two groups according to the dose of HU (10-15.9 mg/kg/day and 16-26 mg/kg/day).
Results:
Nineteen patients were excluded for various reasons. Forty-four children were in the low-dose group and 98 were in the high-dose group. There was significant reduction in the annual number of admissions due to vaso-occlusive crisis in both groups (P < 0.001). However, the difference between the two groups was statistically insignificant (P > 0.05). In addition, there was an observed clinical improvement regarding the acute chest syndrome (ACS). Both groups had comparable significant improvements in their laboratory markers [e.g., hemoglobin (Hb), Mean Corpuscular Volume (MCV), and absolute neutrophil count (ANC)]. All 142 patients tolerated the treatment well. Reversible toxicities occurred in both low- and high-dose groups.
Conclusion:
In SCD patients, low-dose regimen of HU is a feasible option that ensured safety and yet did not affect efficacy.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
